Strengths

Bio-Rad’s current ratio of 3.14 and quick ratio of 2.33 indicate liquidity above many peers, supporting operational resilience through demand cycles.

ROIC of 1.54% is low in absolute terms, but it remains a positive signal that capital deployment is still generating returns rather than destroying value.

A debt-to-equity ratio of 0.17 suggests a comparatively conservative balance sheet versus more levered life-science peers, reducing refinancing pressure.

The company’s liquidity and modest leverage provide flexibility to absorb working-capital swings, which is useful in a business with a 249-day cash conversion cycle.

Weaknesses

A cash conversion cycle of 249 days is structurally long, tying up capital for extended periods and leaving Bio-Rad less efficient than faster-turning peers.

ROIC of 1.54% indicates weak capital productivity, implying the company converts invested capital into operating profit less effectively than stronger peer franchises.

Net debt to EBITDA of 1.28 is manageable, but it still leaves Bio-Rad more exposed than net-cash peers when earnings soften or funding costs rise.

The absence of disclosed margin metrics limits transparency, but the available return profile suggests Bio-Rad lacks the operating leverage seen in top-tier diagnostics peers.

Opportunities

If Bio-Rad shortens its 249-day cash conversion cycle, it could release meaningful working capital and improve peer-relative efficiency without requiring revenue growth.

The company’s low leverage creates room to fund automation, consumables mix improvement, or workflow upgrades that could strengthen positioning versus more constrained peers.

With current and quick ratios already strong, management has flexibility to support inventory availability and customer service levels better than tighter-liquidity competitors.

Any improvement in capital efficiency would have outsized impact because the current ROIC base is low, allowing incremental gains to narrow the gap with peers.

Threats

A prolonged 249-day cash conversion cycle increases exposure to inventory and receivables shocks, making Bio-Rad less resilient than peers with faster cash generation.

Low ROIC leaves limited cushion if pricing pressure or mix deterioration weakens returns, which can quickly widen the gap versus higher-return competitors.

Even moderate leverage can become more burdensome if earnings remain subdued, because Bio-Rad lacks the profitability buffer of stronger peer balance sheets.

If competitors sustain better capital efficiency and faster working-capital turns, Bio-Rad’s relative positioning could erode despite its solid liquidity profile.

Overall Score

Bio-Rad’s balance sheet liquidity is a clear relative support, but weak capital efficiency and an exceptionally long cash conversion cycle keep its structural positioning only moderate versus peers.